| (Values in U.S. Thousands) | Dec, 2016 | Dec, 2015 | Dec, 2014 | Dec, 2013 | Mar, 2026 |
| Sales | 11,470 | 7,750 | 0 | 0 | 0 |
| Sales Growth | +48.00% | unch | unch | unch | unch |
| Net Income | -49,000 | -35,060 | 0 | 0 | 0 |
| Net Income Growth | -39.76% | unch | unch | unch | unch |
Dimension Thera (DMTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Dimension Therapeutics, Inc. is a biotechnology company which focuses on developing novel, liver-directed gene therapy treatments for severe, rare genetic disorders. The company's pipeline of programs includes DTX101, a lead gene therapy product candidate designed to deliver Factor IX, gene expression for hemophilia B; DTX301, a gene therapy product candidate for the treatment of patients with ornithine transcarbamylase deficiency; DTX401, a gene therapy program for the treatment of patients with glycogen storage disease type Ia, a disease that arises from a defect in glucose-6-phosphatase and DTX201, a gene therapy program for the treatment of hemophilia A, which are in different clinical trial stage. Dimension Therapeutics, Inc. is based in Cambridge, Massachusetts.
Fiscal Year End Date: 12/31